SCHEMBL204159

SCHEMBL204159

O=C(CCCCCl)Nc1cnc2ccccc2c1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
BCHE P06276 2/20 0.45
ALDH1A1 P00352 3/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
POLB P06746 1/20 0.45
HDAC3 O15379 7/20 0.44
HDAC1 Q13547 7/20 0.44
HDAC2 Q92769 5/20 0.44
HDAC4 P56524 4/20 0.44
HDAC7 Q8WUI4 4/20 0.44
HDAC10 Q969S8 4/20 0.44
HDAC11 Q96DB2 4/20 0.44
HDAC8 Q9BY41 4/20 0.44
HDAC6 Q9UBN7 4/20 0.44
HDAC9 Q9UKV0 4/20 0.44
HDAC5 Q9UQL6 4/20 0.44
KDM4E B2RXH2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202175 0.92 ALDH1A1 (0.47) KMT2AMEN1BCHEALDH1A1LMNA
SCHEMBL204433 0.88 BCHE (0.47) KMT2AMEN1BCHEALDH1A1LMNA
SCHEMBL671016 0.88 ALDH1A1 (0.54) KMT2AMEN1BCHEALDH1A1LMNA
SCHEMBL29642061 0.88 ALDH1A1 (0.54) KMT2AMEN1BCHEALDH1A1LMNA
SCHEMBL2709571 0.86 HTT (0.51) BCHEALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL20564258 0.86 ALDH1A1 (0.59) KMT2AMEN1BCHEALDH1A1LMNA
SCHEMBL2709340 0.83 ALDH1A1 (0.46) BCHEALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL2682720 0.82 ALDH1A1 (0.47) KMT2AMEN1BCHEALDH1A1LMNA
SCHEMBL203228 0.78 HTT (0.47) KMT2AMEN1ALDH1A1LMNAHTT
SCHEMBL2707298 0.77 KMT2A (0.55) KMT2AMEN1ALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 KMT2A 3293/4885MEN1 4112/4885BCHE 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.